The Pharma Data

AUGUST 16, 2021

Primary and all key secondary endpoints including itch, interference of itch on sleep and quality of life were met at Week 16 in two pivotal Phase 3 trials in lebrikizumab clinical trial program – Safety profile consistent with prior lebrikizumab studies in atopic dermatitis. Almirall S.A.’s About Atopic Dermatitis.

Dermatology 40

Dermatology Trials Bioavailability Medicine 40

The Pharma Data

JUNE 7, 2022

The new findings from the Phase 3 clinical trials (ADvocate 1 and 2) showed eight out of ten patients who achieved clinical response (EASI-75*) with lebrikizumab monotherapy at 16 weeks maintained skin clearance at one year of treatment with the once every two weeks or four weeks regimen. Almirall S.A.’s Source link: [link].

Trials 40

Trials Clinical Trials Clinical Trials Medicine 40

pharmaphorum

OCTOBER 1, 2021

Now, it says the drug has delivered “exciting” results in a proof-of-concept trial. Further details from the study – which involved four doses of either a high or low dose of the antibody over a 12-week period and a clinical assessment at 16 weeks – were presented at the EADV dermatology congress this week. billion upfront.

Drugs 103

Drugs Antibody Dermatology Trials 103

Drug Discovery World

SEPTEMBER 16, 2022

A biologic therapy for very young children with moderate to severe eczema (or atopic dermatitis) has been shown to be safe and effective in an international trial. The therapy is already licensed in the UK for adults and children aged six to 18, and was approved by the FDA in June 2022 for use in younger children.

Antibody 52

Antibody Licensing Licensing Trials 52

The Pharma Data

MARCH 15, 2022

The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the supplemental Biologics License Application (sBLA) for Fasenra (benralizumab) for patients with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP). 2 The trial is expected to read out in the second half of 2023.

Trials 52

Trials Medicine Licensing Licensing 52

The Pharma Data

AUGUST 1, 2021

The approval by the Food and Drug Administration (FDA) was based on efficacy and safety data from the Saphnelo clinical development programme, including two TULIP Phase III trials and the MUSE Phase II trial. 12,13,14,15. 12,13,14,15. Saphnelo is under regulatory review for SLE in the EU and Japan.

Trials 52

Trials Clinical Development Antibody Dermatology 52

The Pharma Data

NOVEMBER 4, 2020

. Initiated CTP-543 THRIVE-AA1 Phase 3 Trial in November 2020. The THRIVE-AA1 Phase 3 trial is a randomized, double-blind, placebo-controlled clinical trial of CTP-543 to evaluate hair regrowth using the Severity of Alopecia Tool (SALT) after 24 weeks of dosing in approximately 700 adult patients with moderate to severe alopecia areata.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Dermatology 52

pharmaphorum

JUNE 2, 2021

In February, the Japanese company reported the results of a 274-patient phase 2 trial which showed that KHK4083 was significantly more effective than placebo at clearing skin lesions at 16 weeks in patients with moderate to severe atopic dermatitis – a condition with more than 60 million sufferers worldwide. In January, Sanofi agreed a $1.45

Drugs 52

Drugs Licensing Licensing Sales 52

pharmaphorum

MAY 4, 2021

There’s a new biotech on the scene after MoonLake Immunotherapeutics launched on a mission to develop sonelokimab, a potential inflammatory diseases drug in-licensed from Germany’s Merck KGaA. The announcement comes a few days after Merck KGaA’s development partner Avillion announced supportive results in a phase 2 psoriasis trial.

Licensing 52

Licensing Licensing Dermatology Antibody 52

The Pharma Data

APRIL 6, 2021

Ongoing research for baricitinib, an oral JAK inhibitor discovered by Incyte and licensed to Lilly, in adult and pediatric AD, alopecia areata (AA), systemic lupus erythematosus (SLE), juvenile idiopathic arthritis (JIA), COVID-19 and for its approved indication for rheumatoid arthritis (RA) continues. Increases of ALT ?5x ADVERSE REACTIONS.

Drugs 52

Drugs Dermatology Clinical Trials Clinical Trials 52

The Pharma Data

AUGUST 17, 2021

Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). As we saw in the GARNET trial, of those patients who respond to treatment with dostarlimab, nearly all continued to respond for six months or longer.”. by blinded independent central review.

FDA Approval 52

FDA Approval Antibody DNA Hormones 52

pharmaphorum

APRIL 26, 2021

The IL-17A and IL-17F inhibitor hit all its objectives in the phase 2 trial, which has now been published in The Lancet, and showed that it was significantly more effective than placebo at clearing up skin lesions in patients with moderate to severe plaque psoriasis.

Antibody 52

Antibody Drugs Marketing Licensing 52

Druggist

DECEMBER 9, 2020

Clobetasone has a narrow licensed use. Dactacort has also antibacterial properties and is one of few over the counter creams licensed for bacterial infections. An interesting licensed use for Eurax cream is the treatment of scabies and itchy skin infestation in the skin. E45 Dermatological Itch Relief Cream, 100g.

Pharmacy 97

Pharmacy Containment Sales Production 97

The Pharma Data

AUGUST 19, 2021

entered into a license and collaboration agreement with Yuhan Corporation for the development of lazertinib. Dermatologic Adverse Reactions 7. For Grade 3 reactions, add oral steroids and consider dermatologic consultation. 8] , [9] , [10] , [11] , [12]. 8] , [9] , [10] , [11] , [12]. **In In 2018, Janssen Biotech, Inc.

FDA Approval 52

FDA Approval Dermatology Genetics Development 52

The Pharma Data

NOVEMBER 8, 2020

Almirall strengthens its leadership in medical dermatology by reinforcing its management team in France and obtaining reimbursement in France of Ilumetri ® (tildrakizumab) for treating moderate to severe chronic plaque psoriasis in adults. Dermatology shows resilience in Europe and initial signs of recovery in the US.

Dermatology 52

Dermatology Sales Marketing Production 52

XTalks

MAY 22, 2023

According to Allergan Aesthetics, SkinVive is slated for commercial availability within the next six months, exclusively through licensed physicians and practitioners. I am excited to add this unique offering to my dermatologic treatment regimen for my patients,” added Dr.

Filler 92

Filler FDA Approval Dermatology Production 92

pharmaphorum

JUNE 8, 2021

It’s the second unusual royalty-focused deal to be entered into by a biotech in the last few days, after MorphoSys signed over future revenues from out-licensed medicines to fund its $1.7 It is also due to start a phase 3 trial in atopic dermatitis later this year. billion takeover of Constellation Pharma. billion product.

Sales 52

Sales Dermatology Licensing Licensing 52

The Pharma Data

JANUARY 13, 2021

Fast Track designation is well-timed, as we anticipate starting our Phase 2 clinical trial in hospitalized COVID-19 patients this month, and should help bring Brilacidin to patients faster in these dire times.”. Brilacidin for UP/UPS was licensed to Alfasigma S.p.A.

Clinical Trials 52

Clinical Trials Clinical Trials Trials In-Vitro 52

The Pharma Data

MARCH 4, 2021

associate professor of Dermatology at Yale School of Medicine. AA is the second potential treatment indication in dermatology for baricitinib after AD. ” Baricitinib is an oral JAK inhibitor discovered by Incyte and licensed to Lilly. 10x ULN were observed in patients in Olumiant clinical trials. Increases of ALT ?5x

Trials 52

Trials Development Dermatology Clinical Trials 52

The Pharma Data

JULY 8, 2021

Tezepelumab is the first and only biologic to consistently and significantly reduce asthma exacerbations in a broad population across Phase II and III clinical trials. The BLA was based on results from the PATHFINDER clinical trials programme, including results from the pivotal NAVIGATOR Phase III trial.

Trials 52

Trials Medicine Sales Clinical Trials 52

The Pharma Data

JANUARY 24, 2021

With a presidential inauguration and a federal holiday, it wasn’t an enormously busy week for clinical trial news, but there was a fair amount, nonetheless. It inked a deal with the National Institute of Allergy and Infectious Diseases (NIAID) to launch a Phase I trial. Read on to see. COVID-19-Related. Non-COVID-19-Related.

Trials 52

Trials Allergies In-Vitro Antibody 52

The Pharma Data

AUGUST 3, 2021

We expect that recovery in the dermatology segment will continue to progress over the coming quarters. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). and continued geographic expansion, including the launch in China. Tezepelumab.

Sales 52

Sales Production Antibody Development 52

The Pharma Data

APRIL 26, 2021

COVID-19 negatively impacted demand, particularly: dermatology, ophthalmology, the breast cancer portfolio, Sandoz Retail and Anti-Infectives. billion declined, mainly due to the USD 650 million upfront payment to in-license tislelizumab from BeiGene. Adakveo sales reached USD 37 million. Free cash flow¹ of USD 1.6

Sales 40

Sales Medicine Production Manufacturing 40

The Pharma Data

SEPTEMBER 15, 2020

Limited blinded tolerability data from the ongoing Phase 3 trial, confirming the mostly mild to moderate tolerability profile as was observed in Phase 1. In the blinded data presented, 50% of trial participants received placebo and 50% received BNT162b2. A Phase 3 trial is ongoing. Protease Inhibitor Program. Rare Disease.

Gene Therapy 52

Gene Therapy Vaccination Vaccine Trials 52

XTalks

AUGUST 2, 2023

This is largely due to failed trials as a prophylaxis resulting in the European Committee for Medical Products (CHMP) recommending against the approval of Lagevrio. There was a record 34 approvals in major markets, and late-stage trials are commencing for medications including camizestrant, datopotamab deruxtecan and volrustomig.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

Delveinsight

AUGUST 13, 2020

SAR440340 History: Regeneron and Sanofi are currently studying REGN3500 in respiratory and dermatological diseases where inflammation is thought to play an underlying role. REGN3500 is being studied in Phase II trials for asthma, chronic obstructive pulmonary disease and atopic dermatitis. The drug is available for patients with COPD.

Antibody 40

Antibody Medicine Trials Development 40

Pharma Marketing Network

OCTOBER 27, 2020

So a doctor that’s licensed stay only in the state of New York would be able to practice across the entire counties using Telemedicine.

Insulin 52

Insulin Marketing Doctors Doctor 52

Pharma Marketing Network

OCTOBER 27, 2020

So a doctor that’s licensed stay only in the state of New York would be able to practice across the entire counties using Telemedicine.

Insulin 52

Insulin Doctors Doctor Marketing 52